Eucalyptus globulus · essential_oil
Evidence tier: limited
Mucolytic agent that opens airways, thins mucus, and relieves congestion, 1,8-cineole is one of the best evidenced compounds for respiratory support
1,8-cineole (eucalyptol) is the active constituent and the one every trial standardises on. It is credited with mucolytic and secretolytic activity, bronchodilation, and suppression of airway inflammation, and the anti inflammatory work in airway cells is the best characterised part of the story. The mechanism is also the hazard: cineole's action on the airway is exactly why EMA contraindicates it in the under 30 months, where it can trigger laryngospasm.
Limited, and the record only makes sense once you separate two products that get talked about as one. EUCALYPTUS OIL, the thing sold as eucalyptus, is registered by EMA HMPC as a TRADITIONAL herbal medicinal product, for relief of cough associated with the common cold and for symptoms of localised muscle pain. Traditional registration means efficacy was not demonstrated by clinical trials; EMA's own framing is that effectiveness 'is plausible' and that safe use over 30 years has been shown. PURIFIED 1,8-CINEOLE IN CAPSULES is a different product with a different evidence base, and it is where the trials live. Worth et al. (2009) randomised 242 patients with STABLE COPD to 200 mg of cineole three times daily or placebo for six months and found a significant reduction in the frequency, duration and severity of exacerbations, though the secondary endpoints (lung function, breathlessness, quality of life) did NOT reach statistical significance. Juergens has separately trialled cineole in asthma and in rhinosinusitis. Note what that means: the best evidence for the eucalyptus story comes from a purified drug like capsule, given as ADD ON therapy, in a DIAGNOSED DISEASE POPULATION (COPD), and it does not transfer to a person with a blocked nose inhaling oil over a bowl. SAFETY IS THE LOAD BEARING PART OF THIS RECORD. EMA is explicit: eucalyptus oil must NOT be given to children under 30 months of age because of the risk of spasm of the larynx, and must not be given to children with a history of seizures with or without fever. Oral forms are for adults and adolescents 12 and over only; inhalation, topical and bath preparations are permitted only from 4 years. Bath preparations are contraindicated with large skin injuries, open wounds, acute skin disease, high fever, severe infections, circulatory problems or heart failure.
Two different products. As purified 1,8-cineole capsules, the dose used in the COPD trial is 200 mg three times daily. As eucalyptus oil under EMA traditional registration, oral use is restricted to adults and adolescents over 12, and inhalation, topical or bath use to children from 4 years. Contraindicated under 30 months by any route. Seek advice if cough persists beyond 1 week, or muscle pain beyond 1 to 2 weeks.
Inhalation: add 2 to 3 drops of eucalyptus oil to hot water and inhale steam for 5 to 10 minutes. Internal (oral, standardised): 200mg of cineole standardised extract three times daily for sinusitis or bronchitis support. Do not use undiluted oil internally.
CONTRAINDICATED in children under 5 for steam inhalation or facial application, 1,8-cineole can cause respiratory depression and laryngospasm. Adults with asthma should use with caution, may trigger bronchospasm in some. Do not ingest eucalyptus oil, toxic above 3.5 mL in adults. Brain only: requires Remy screening for age and asthma history.
Pregnancy: avoid
Breastfeeding: avoid
Active compounds: 1,8-cineole (eucalyptol), alpha-pinene, limonene
Remedies using Eucalyptus · Browse by body system · Check it against what you take
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.